Results 11 to 20 of about 18,687 (213)

Anion-Controlled Structural Interconversion of Palladium Cages Enables Separations by Selective Guest Capture and Release. [PDF]

Angew Chem Int Ed Engl
We report a pair of interconvertible palladium(II) cages assembled from an asymmetric ligand, whose switching is triggered by specific counter‐anions, tetrafluoroborate (BF4−) and bis(trifluoromethanesulfonyl)imide (NTf2−). Their complementary guest preferences enable orthogonal, multi‐cycle catch‐and‐release, exemplified by the selective purification ...
Li Z, Ronson TK, McTernan CT.
europepmc   +3 more sources

Exploring the impact of baseline and on-treatment variables on durability of responses to fostemsavir through weeks 96 and 192 in the phase 3 BRIGHTE study. [PDF]

HIV Med
Abstract Objectives The gp120‐directed attachment inhibitor fostemsavir was effective in people with multidrug‐resistant (MDR) HIV‐1 in the BRIGHTE study. Understanding factors associated with virologic response can help clinicians optimize treatment and identify individuals for fostemsavir‐based regimens.
Gartland M, Wang X, Liao Q, Li B, Du F, Krystal M, Tenorio AR, Pierce A, Castillo-Mancilla JR.   +8 more
europepmc   +2 more sources

Pooled resistance analyses of darunavir once-daily regimens and formulations across 10 clinical studies of treatment-naïve and treatment-experienced patients with human immunodeficiency virus-1 infection

HIV Research & Clinical Practice, 2020
Background The efficacy and high barrier to resistance of darunavir have been demonstrated across diverse populations with HIV-1 infection. Objective To evaluate post-baseline resistance among patients in studies of once-daily (QD) darunavir-based ...
Erkki Lathouwers, Sareh Seyedkazemi, Donghan Luo, Kimberley Brown, Sandra De Meyer, Eric Y. Wong   +5 more
doaj   +1 more source

Comprehensive Study of Antiretroviral Drug Permeability at the Cervicovaginal Mucosa via an In Vitro Model

Pharmaceutics, 2022
Modulation of drug transporter activity at mucosal sites of HIV-1 transmission may be exploited to optimize retention of therapeutic antiretroviral drug concentrations at target submucosal CD4+ T cells.
Constandinos Carserides, Kieron Smith, Marta Zinicola, Abhinav Kumar, Magda Swedrowska, Carlo Scala, Gary Cameron, Zoe Riches, Francesco Iannelli, Gianni Pozzi, Georgina L. Hold, Ben Forbes, Charles Kelly, Karolin Hijazi   +13 more
doaj   +1 more source

Rapid initiation of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in acute and early HIV-1 infection: a DIAMOND subgroup analysis

HIV Research & Clinical Practice, 2021
Background: Treatment during acute or early human immunodeficiency virus (HIV)-1 infection is associated with immunologic and virologic benefits. Objective: To evaluate darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) efficacy/safety ...
Keith Dunn, Rachel Rogers, Richard Bruce Simonson, Donghan Luo, Shubin Sheng, Purnima T. Kassam, Sareh Seyedkazemi, Hélène Hardy   +7 more
doaj   +1 more source

Preferred antiretroviral drugs for the next decade of scale up [PDF]

, 2012
Global commitments aim to provide antiretroviral therapy (ART) to 15 million people living with HIV by 2015, and recent studies have demonstrated the potential for widespread ART to prevent HIV transmission.
Andrieux-Meyer, Isabelle, Cahn, Pedro, Calmy, Alexandra, Clayden, Polly, Ford, Nathan, Goemaere, Eric, Katlama, Christine, Levin, Andrew, Lynch, Sharonann, Raguin, Gilles, Vitoria, Marco   +10 more
core   +4 more sources

The Effect of Solvents and Drying Temperature on the Physicochemical Properties of Darunavir and Darunavir Ethanolate Substances

Разработка и регистрация лекарственных средств, 2021
Introduction. Usage of aggressive conditions (solvents, high temperature, etc.) in a dosage form manufacturing can lead to a change in the properties of a pharmaceutical substance.
S. A. Zolotov, I. A. Dain, N. B. Demina, A. S. Zolotova, E. S. Ponomarev   +4 more
doaj   +1 more source

Drug-Drug Interactions Among Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Medications [PDF]

, 2015
One-fourth of individuals diagnosed with the human immunodeficiency virus concomitantly have the hepatitis C virus infection. Since the discovery of highly active antiretroviral therapy, liver complications have become the leading cause of morbidity and ...
Gandhi, Mona A., Kaur, Kirpal, Slish, Judianne   +2 more
core   +2 more sources

Acute myocardial infarction associated with abacavir and tenofovir based antiretroviral drug combinations in the United States

AIDS Research and Therapy, 2021
Introduction Although individual antiretroviral drugs have been shown to be associated with elevated cardiovascular disease (CVD) risk, data are limited on the role of antiretroviral drug combinations.
Kunchok Dorjee, Manisha Desai, Tsering Choden, Sanjiv M. Baxi, Alan E. Hubbard, Arthur L. Reingold   +5 more
doaj   +1 more source

Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1–Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial

AIDS Research and Treatment, 2012
Objectives. Evaluation of pharmacokinetics and pharmacodynamics of darunavir and etravirine among HIV-1–infected, treatment-experienced adults from GRACE, by sex and race. Methods.
Thomas Kakuda, Vanitha Sekar, Peter Vis, Bruce Coate, Robert Ryan, David Anderson, Guy De La Rosa, Joseph Mrus   +7 more
doaj   +1 more source